{"id":"gnr-067","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":{"chemblId":"CHEMBL5843164","moleculeType":null,"molecularWeight":"379.49"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"GNR-067 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels. This mechanism is similar to other SGLT2 inhibitors, such as empagliflozin and canagliflozin.","oneSentence":"GNR-067 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:14:07.945Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT04667039","phase":"PHASE3","title":"Efficacy, Safety, pharmacokinetiсs, Immunogenicity of GNR-067 and Lucentis®","status":"UNKNOWN","sponsor":"AO GENERIUM","startDate":"2022-03-20","conditions":"Age Related Macular Degeneration (ARMD)","enrollment":408}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ranibizumab"],"phase":"phase_3","status":"active","brandName":"GNR-067","genericName":"GNR-067","companyName":"AO GENERIUM","companyId":"ao-generium","modality":"Biologic","firstApprovalDate":"","aiSummary":"GNR-067 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}